Clinical Trials Logo

Filter by:
NCT ID: NCT05794438 Completed - Clinical trials for Addiction, Substance

Gamified Adaptive Approach Bias Modification on Individuals With Methamphetamine Use History

Start date: March 10, 2023
Phase: N/A
Study type: Interventional

A randomized controlled trial will be conducted to investigate whether a proposed algorithm that adjusts the congruency ratio based on the user's performance and difficulty can enhance the effectiveness of approach bias modification. Methamphetamine users will be recruited and randomized into an algorithm group, a standard group, and a control group.

NCT ID: NCT05794425 Recruiting - Clinical trials for Bone Marrow Failure Disorders

Clinical Study of UCB Combined With UC-MSCs in the Treatment of Bone Marrow Failure Disorders

Start date: August 1, 2023
Phase: Phase 1/Phase 2
Study type: Interventional

The multicenter collaborative clinical study conducted a systematic clinical observation in the treatment of bone marrow failure diseases via UCB&UC-MSCs , in order to observe its clinical efficacy and safety.

NCT ID: NCT05794152 Recruiting - Clinical trials for Gestational Diabetes Mellitus

Wenzhou Gestational Diabetes Cohort

WGDC
Start date: March 21, 2023
Phase: N/A
Study type: Interventional

The Wenzhou Gestational Diabetes Cohort (WGDC) is a prospective cohort study among women with gestational diabetes mellitus (GDM) during pregnancy and their offspring living in Wenzhou, China. The primary aim of this cohort is to characterize the continuous blood glucose response to dietary intake and physical activity among pregnant women with GDM over 2 weeks, and to facilitate the development of personalized nutritional/lifestyle recommendation among these patients. Another aim of the WGDC is to investigate the association of dietary and physical activity together with continuous glucose change during pregnancy on the adverse birth outcomes including preterm birth, macrosomia and large-for-gestational-age birth. The secondary aim is to investigate the prospective associations of diet, physical activity and continuous glucose change over 2 weeks among the patients with long-term metabolic health of the women and their offspring.

NCT ID: NCT05793892 Not yet recruiting - Analgesia Clinical Trials

Efficacy and Safety of Lidocaine and Tetracaine Cream for Facial Laser Aesthetics in Chinese Adults

Start date: March 31, 2023
Phase: Phase 3
Study type: Interventional

Lattice laser is a new medical cosmetic technology, which is a kind of noninvasive and invasive technology. Compared with traditional laser therapy, lattice laser has a wider range of clinical use, and can be used to treat skin problems such as acne marks, fine wrinkles, skin aging, chloasma, coffee spots, large pores and dullness. Dot-array laser has been widely used in the treatment of skin diseases and skin cosmetics because of its advantages of small trauma, rapid recovery, safety and effectiveness, and fewer complications. The facial skin is rich in nerve fibers and pain receptors are distributed punctuately. Most patients have pain and discomfort to varying degrees during laser treatment. The pain and discomfort associated with laser treatment of the face make anaesthesia an important assistant technique in laser skin cosmetology. At present, the commonly used anesthesia methods to relieve pain include: local cooling anesthesia, topical anesthesia, general anesthesia, gas inhalation anesthesia, intravenous anesthesia, iontophoresis anesthesia, etc. General anesthesia is usually associated with a risk of complications, residual areas of regional nerve block are often sensitive to pain, and acupuncture and drug injection can increase patient discomfort. Therefore, because of its simplicity and convenience of drug administration, topical anesthesia has a positive significance in facial lattice laser cosmetic treatment. The reference product lidocaine tetracaine cream (brand name: Pliaglis ®) has been marketed in the United States and the European Union for many years, and its therapeutic efficacy has been clinically recognized and has a good safety profile.Lidocaine tetracaine cream (R & D code: CU-30101) is manufactured by Cutia Therapeutics (Wuxi) Co., Ltd . A randomized, double-blind, multi-center clinical study is currently proposed to evaluate the efficacy and safety of CU-30101 in facial spot-array laser cosmetology in Chinese subjects with Pliaglis ® as a control.

NCT ID: NCT05793749 Recruiting - Lymphedema Clinical Trials

Early Intervention to Prevent Lower Limb Lymphedema of Gynecological Malignancy

Start date: April 1, 2023
Phase: N/A
Study type: Interventional

This study is a prospective, randomized, controlled clinical trial of a single center in China and plans to enroll 400 patients. 1. Patients with diagnosed gynecological malignancies who underwent pelvic and abdominal lymphadenectomy and required pelvic radiotherapy; 2. Random grouping (A:B=3:1): A. Prophylactic lymphoedema treatment; B. Standard care group; 3. Preventive lymphedema health education was given to patients with gynecological malignant tumors without contraindications before surgery. All patients were randomly divided into an intervention group and a nonintervention group. The intervention group received preventive lymphedema treatment twice a week. 10 times, and the interval between the two treatments was not less than 48 hours and not more than 2 weeks. The intervention measures included four parts: manual lymphatic drainage, skin care, functional exercise, and wearing lymphedema preventive compression stockings. In the nonintervention group, knowledge education and telephone follow-up were routinely conducted. 4. All patients were evaluated for edema, lymphedema symptoms and quality of life 1 day before radiotherapy, every Friday during radiotherapy and every 3 months thereafter. Bioelectrical impedance measurement and leg diameter measurement were used to evaluate edema, the Gynecologic Cancer Lymphedema Questionnaire (GCLQ) was used to evaluate lymphedema symptoms, and the EORTC Quality of Life Scale (QLQ-C30) was used to evaluate quality of life. followed up to 2 years after the end of lymphedema prophylaxis.

NCT ID: NCT05793450 Completed - Renal Impairment Clinical Trials

Pharmacokinetics of IBI362 in Subjects With and Without Renal Impairment

Start date: May 5, 2023
Phase: Phase 1
Study type: Interventional

The purpose of this study is to assess how fast IBI362 gets into the blood stream and how long it takes the body to remove it in participants with impaired kidney function compared to healthy participants.

NCT ID: NCT05793437 Completed - Hypercapnia Clinical Trials

Effects of Permissive Hypercapnia on Concentration of Postoperative Plasma Neurofilament Light

Start date: April 1, 2023
Phase: N/A
Study type: Interventional

The aim of this study is to conduct a prospective, single-center randomized controlled study to investigate the changes of plasma NFL concentration in patients undergoing laparoscopic surgery with mild hypercapnia, and further explore its impact on the central nervous system.

NCT ID: NCT05793307 Recruiting - Clinical trials for Pompe Disease Infantile-Onset

Evaluation of the Safety and Efficacy of Infantile-onset Pompe Disease Gene Therapy Drug

Start date: June 2, 2023
Phase: Phase 1/Phase 2
Study type: Interventional

This study is being conducted to evaluate the safety and effectiveness of GC301 adeno-associated virus vector expressing codon-optimized human acid alpha-glucosidase (GAA) as potential gene therapy for Pompe disease. Patients diagnosed with infantile-onset Pompe disease who are younger than 6 months old will be studied.

NCT ID: NCT05793229 Completed - Frailty Syndrome Clinical Trials

Frailty Trajectories and Their Association With Health Outcomes

Start date: March 1, 2021
Phase:
Study type: Observational

Frailty is common in gastric cancer survivors and seriously affects their prognosis. Multiple longitudinal follow-up assessment of frailty could provide a better understanding of the frailty change of individuals. Our aims were to identify the longitudinal trajectories of frailty and estimate their association with health outcomes in elderly gastric cancer survivors.

NCT ID: NCT05793164 Completed - Folliculitis Clinical Trials

Characterization and Risk Factors of Folliculitis After Hair Transplantation

Start date: January 1, 2018
Phase:
Study type: Observational

We retrospectively reviewed 1317 patients who had undergone HT and completed 9-month follow-up between January 2018 and June 2021 at 4 medical centers. The incidence of postoperative folliculitis and the patient demographics were assessed. Logistic regression analysis was used to identify the risk factors, and the characteristics of different types of folliculitis were compared.